Presentation The Diabetes Nerd Podcast: Real Science with Seraxis CEO Will Rust admin September 25, 2026
Press Release Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated T1D Biotech Company admin September 10, 2026
Press Release Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes admin October 15, 2024
In the news ENDPOINTS NEWS: Maryland biotech gets green light for stem cell-derived therapy for diabetes, aiming to compete with Vertex admin October 15, 2024
Press Release Seraxis wins grant from Maryland Stem Cell Research Fund to accelerate development of allogenetically compatible pancreatic islet replacement therapy for functional cure of T1D. admin June 14, 2024
Press Release Seraxis’ manufacturing suite completes GMP quality system audit ahead of SR-02 IND filing and transplantation of pancreatic clusters to patients with Type 1 Diabetes. admin January 4, 2024
Publication The transcription factors ISL-1 and MAFA, but not NKX6-1 Characterize a Stem-cell Derived Population of Endocrine Pancreatic Cells Capable of Controlling blood Glucose in Rodent Models of Diabetes. admin December 31, 2023
